Sheldon Koenig is President and Chief Executive Officer of Esperion Therapeutics, Inc. (ESPR). The company reported total compensation of $3,535,512 for fiscal year 2025.
| Salary | $770,833 |
|---|---|
| Bonus | $0 |
| Stock awards | $1,260,000 |
| Option awards | $847,929 |
| Non-equity incentive plan | $639,375 |
| Pension and non-qualified deferred compensation | $0 |
| All other compensation | $17,375 |
| Total | $3,535,512 |
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed, without adjustment.
Cited to the compensation disclosure Esperion Therapeutics, Inc. filed April 16, 2026, accession 0001628280-26-025499.
| Fiscal year | Role | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | President and Chief Executive Officer | $770,833 | $0 | $1,260,000 | $847,929 | $639,375 | $0 | $17,375 | $3,535,512 |
| FY2024 | President and Chief Executive Officer | $745,833 | $0 | $930,700 | $982,162 | $487,500 | $0 | $29,045 | $3,175,240 |
Totals as disclosed in each year's own compensation disclosure for Esperion Therapeutics, Inc..
| Named executive officer | Role | FY2025 total |
|---|---|---|
| Sheldon Koenig this page | President and Chief Executive Officer | $3,535,512 |
| John Harlow | Chief Commercial Officer | $2,813,103 |
| Benjamin Halladay | Chief Financial Officer | $1,351,935 |
The company's named executive officers for fiscal year 2025, and what it reported for each. See the full Esperion Therapeutics, Inc. compensation brief.
Sheldon Koenig's compensation sits inside Esperion Therapeutics, Inc.'s full executive and board picture — the peer group, pay against peers, incentive design and the board itself.